About Importin subunit alpha-6
Importin subunit alpha-6 (KPNA5) is a protein
from Homo sapiens identified by UniProt accession
O15131, 539 residues long.
MolForge cross-references it against 0 known binders and
22 disease associations.
Target properties
| Protein name | Importin subunit alpha-6 |
| UniProt accession | O15131 |
| Gene | KPNA5 |
| Organism | Homo sapiens |
| Length | 539 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (22)
Diseases linked to this target (Open Targets).
- influenza · score 0.46
- metabolite measurement · score 0.10
- eosinophil count · score 0.02
- COVID-19 · score 0.02
- lung adenocarcinoma · score 0.01
- ovarian carcinoma · score 0.01
- Sepsis · score 0.01
- septic shock · score 0.01
- pachyonychia congenita · score 0.01
- colorectal cancer · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O15131-F1 | alphafold | PREDICTED | 85.89 | — |
Amino-acid sequence (539 residues)
MDAMASPGKD NYRMKSYKNK ALNPQEMRRR REEEGIQLRK QKREEQLFKR RNVYLPRNDE SMLESPIQDP DISSTVPIPE EEVVTTDMVQ MIFSNNADQQ LTATQKFRKL LSKEPNPPID QVIQKPGVVQ RFVKFLERNE NCTLQFEAAW ALTNIASGTF LHTKVVIETG AVPIFIKLLN SEHEDVQEQA VWALGNIAGD NAECRDFVLN CEILPPLLEL LTNSNRLTTT RNAVWALSNL CRGKNPPPNF SKVSPCLNVL SRLLFSSDPD VLADVCWALS YLSDGPNDKI QAVIDSGVCR RLVELLMHND YKVVSPALRA VGNIVTGDDI QTQVILNCSA LPCLLHLLSS PKESIRKEAC WTVSNITAGN RAQIQAVIDA NIFPVLIEIL QKAEFRTRKE AAWAITNATS GGTPEQIRYL VALGCIKPLC DLLTVMDSKI VQVALNGLEN ILRLGEQESK QNGIGINPYC ALIEEAYGLD KIEFLQSHEN QEIYQKAFDL IEHYFGVEED DPSIVPQVDE NQQQFIFQQQ EAPMDGFQL
Explore Importin subunit alpha-6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets